Woodmont Investment Counsel LLC Purchases 445 Shares of Harrow, Inc. (NASDAQ:HROW)

Woodmont Investment Counsel LLC boosted its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 0.5% in the 4th quarter, HoldingsChannel reports. The fund owned 81,400 shares of the company’s stock after buying an additional 445 shares during the quarter. Woodmont Investment Counsel LLC’s holdings in Harrow were worth $2,731,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Harrow by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company’s stock worth $62,809,000 after buying an additional 5,225 shares during the period. State Street Corp lifted its stake in shares of Harrow by 2.2% in the 3rd quarter. State Street Corp now owns 730,973 shares of the company’s stock valued at $32,865,000 after purchasing an additional 15,554 shares during the period. Geode Capital Management LLC increased its position in Harrow by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock valued at $32,500,000 after buying an additional 3,960 shares in the last quarter. Braidwell LP increased its position in Harrow by 47.9% during the 3rd quarter. Braidwell LP now owns 439,638 shares of the company’s stock valued at $19,766,000 after buying an additional 142,450 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Harrow by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company’s stock valued at $8,563,000 after buying an additional 3,589 shares in the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $57.00 target price on shares of Harrow in a report on Tuesday, March 18th. B. Riley dropped their price target on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research note on Wednesday, December 4th.

Harrow Price Performance

Shares of Harrow stock opened at $28.41 on Monday. The stock’s 50-day simple moving average is $29.51 and its 200-day simple moving average is $38.38. Harrow, Inc. has a 52 week low of $9.86 and a 52 week high of $59.23. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -30.22 and a beta of 0.69. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.